Stocks Health care CLDX
NASDAQ · Health careCelldex Therapeutics, Inc. (CLDX)
It posted a net loss of $309.1M. In fiscal 2025 capital spending exceeded operating cash flow by $213.7M. At September 30, 2026 it held $27M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Celldex Therapeutics, Inc.
- Net worth
- Celldex Therapeutics, Inc. has a market value (market cap) of $2.4B at the latest share price, and shareholders' equity of $649.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.5M (-78.0% year on year), with a net loss of $258.8M.
- Cash flow
- In fiscal 2025 operations used $210.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Celldex Therapeutics, Inc.'s next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Celldex Therapeutics, Inc. does
Celldex Therapeutics, Inc. is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker CLDX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.5M | -$258.8M | -$3.90 | -$213.7M |
| 2024 | $7M | -$157.9M | -$2.45 | -$159.7M |
| 2023 | $6.9M | -$141.4M | -$2.92 | -$109.1M |
| 2022 | $2.4M | -$112.3M | -$2.40 | -$105.6M |
| 2021 | $4.7M | -$70.5M | -$1.64 | -$62.2M |
| 2020 | $7.4M | -$59.8M | -$2.02 | -$42M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CLDX ranks in Health care
Latest SEC filings
What Celldex Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- November 5, 2026
- October 7, 2026Passive stake changed SCHEDULE 13G/A
- September 22, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 97% to $22K versus the same quarter last year; diluted EPS -$0.94 versus -$0.85.
- August 6, 2026
- July 15, 2026
Insider trades
What the people running Celldex Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| January 2, 2026 | Martin Samuel BatesSVP AND CFO | Exercised options | 4,817 | $50K |
| December 15, 2025 | Pepin RonaldSR. VP & CBO | Exercised options | 8,333 | $75.1K |
| December 15, 2025 | Pepin RonaldSR. VP & CBO | Exercised options | 11,000 | $30.6K |
| December 4, 2025 | Jimenez Freddy A.SVP & GENERAL COUNSEL | Sold | 4,166 | $121.2K |
| November 13, 2025 | Wright Richard M.Former Officer | Exercised options | 6,876 | $62K |
| November 13, 2025 | Wright Richard M.Former Officer | Exercised options | 26,672 | $276.9K |
| November 13, 2025 | Wright Richard M.Former Officer | Exercised options | 15,750 | $354.1K |
| November 13, 2025 | Wright Richard M.Former Officer | Sold | 49,298 | $1.2M |
Who owns CLDX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Wellington Management Group LLP13G, passive with 3 related filers | 12.2% | February 10, 2026 |
| Kynam Capital Management, LP13G, passive with 2 related filers | 6.78% | August 14, 2026 |
| T. Rowe Price Associates, Inc.13G, passive | 6% | August 14, 2026 |
| Fmr LLC13G, passive with 1 related filers | 5.6% | May 6, 2026 |
| Vanguard Capital Management13G, passive | 5.17% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 253 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Wellington Management Group Llp | 9,543,671 | +983,195 |
| BlackRock, Inc. | 7,002,530 | +1,632,645 |
| Kynam Capital Management, LP | 5,322,908 | -517,659 |
| State Street Corp | 3,900,427 | +1,096,259 |
| Fmr LLC | 3,722,888 | -26,160 |
| Vanguard Capital Management LLC | 3,464,831 | +503,936 |
| Deep Track Capital, LP | 2,939,151 | +1,655,172 |
| Logos Global Management LP | 2,100,000 | +1,650,000 |
| Geode Capital Management, LLC | 2,022,226 | +334,152 |
| Eversept Partners, LP | 1,785,941 | -2,075 |
| Goldman Sachs Group Inc | 1,615,343 | +626,927 |
| Assenagon Asset Management S.A. | 1,577,392 | +1,430,867 |
| Commodore Capital LP | 1,350,000 | -1,346,616 |
| Bellevue Group AG | 1,200,000 | 0 |
| Baker Bros. Advisors LP | 1,182,611 | +517,241 |
| Millennium Management LLC | 1,170,787 | -82,745 |
| Dimensional Fund Advisors LP | 1,073,985 | +14,451 |
| American Century Companies Inc | 1,042,395 | +186,085 |
| Eventide Asset Management, LLC | 1,037,000 | 0 |
| Novo Holdings A/S | 1,025,000 | -175,000 |
Insiders
4 insiders reported holding 104,668 shares in total, about $3.2M at the last price.
| Holder | Shares |
|---|---|
| Martin Samuel BatesSVP AND CFO | 32,942 |
| Jimenez Freddy A.SVP & GENERAL COUNSEL | 30,796 |
| Wright Richard M.Former Officer | 20,833 |
| Pepin RonaldSR. VP & CBO | 20,097 |
Questions about CLDX
What does Celldex Therapeutics, Inc. do?
Celldex Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as CLDX. Its shares trade on NASDAQ under the ticker CLDX.
What is Celldex Therapeutics, Inc.'s net worth?
Celldex Therapeutics, Inc. has a market value (market cap) of $2.4B at the latest share price, and shareholders' equity of $649.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Celldex Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $309.1M.
When did Celldex Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Celldex Therapeutics, Inc.'s next earnings report?
Celldex Therapeutics, Inc.'s next report is expected around February 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CLDX with
Follow CLDX
Get an email when Celldex Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Celldex Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.